Cagrilintide + Tirzepatide
Why this combination
This combination layers three appetite mechanisms by pairing the long-acting amylin analog cagrilintide with the dual-incretin agonist tirzepatide (GIP + GLP-1). The logic directly mirrors CagriSema — which combines amylin with GLP-1 — but substitutes tirzepatide, whose added GIP activity already produces some of the largest weight-loss figures of any approved single molecule (up to roughly 21% in SURMOUNT-1). Stacking amylin-mediated satiety on top is intended to push appetite suppression further still.
The mechanisms are genuinely complementary rather than redundant: amylin slows gastric emptying and signals fullness through amylin/calcitonin receptor complexes, while the incretins act on GIP and GLP-1 receptors to drive satiety, glucose-dependent insulin secretion, and glucagon suppression. Because cagrilintide and tirzepatide are both engineered for once-weekly dosing, their schedules align cleanly.
This is a community/experimental construction — there is no dedicated trial of cagrilintide plus tirzepatide (the amylin-plus-incretin clinical program is CagriSema, with semaglutide). It is presented at community confidence: each component is well studied individually, but their combined efficacy and safety are extrapolated, not measured.
Per-compound dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Cagrilintide | 0.3 → 2.4 mg | Once weekly | Titrated upward in parallel; mirrors the CagriSema cagrilintide schedule. |
| Tirzepatide | 2.5 → 15 mg | Once weekly | Standard tirzepatide titration: 2.5 mg start, stepping up ~2.5 mg every 4 weeks as tolerated. |
Reconstitution math
For educational and research reference only. Not intended for human consumption, not medical advice. Compounds discussed are sold and used for laboratory research purposes only.
Separate vials
Cagrilintide — reconstitute a 10 mg vial with 2 mL bacteriostatic water → 5,000 mcg/mL. A 2.4 mg (2,400 mcg) maintenance dose is 0.48 mL (48 units); the 0.3 mg starting dose is 0.06 mL (6 units).
Tirzepatide — reconstitute a 30 mg vial with 2 mL → 15,000 mcg/mL. A 10 mg (10,000 mcg) dose is 0.667 mL (66.7 units); a 5 mg dose is 0.333 mL (33.3 units). For 15 mg, a 60 mg vial + 3 mL → 20,000 mcg/mL gives 0.75 mL (75 units).
Separate vials are strongly preferred so each compound can be titrated on its own four-week schedule — the safer approach during escalation.
Pre-blended (single vial)
Pre-blending at full maintenance doses is impractical: a combined 2.4 mg cagrilintide + 10–15 mg tirzepatide draw approaches or exceeds a full 100-unit syringe, and the two titrate on independent schedules.
Early-phase worked example only: combine cagrilintide 5 mg + tirzepatide 10 mg and add 2 mL → cagrilintide is 2,500 mcg/mL and tirzepatide is 5,000 mcg/mL. A 0.12 mL draw (12 units) then delivers 300 mcg cagrilintide and 600 mcg tirzepatide — usable for the lowest starting phase, but it locks the ratio, so revert to separate vials once you begin stepping the doses.
Verify any blend with the reconstitution calculator before dosing — concentrations change for every compound when you alter the water volume.
Cycle length & alternatives
- Cycle length
- Used as a long-term weight-management regimen rather than a fixed cycle; titration occupies roughly the first 16–20 weeks, mirroring tirzepatide and CagriSema escalation.
- Compared to alternatives
- Versus CagriSema (cagrilintide + semaglutide), this swaps a GLP-1 agonist for tirzepatide's dual GIP/GLP-1 mechanism, theoretically a stronger incretin base — but CagriSema has a dedicated Phase 3 program (REDEFINE) behind it, whereas this pairing does not. Versus tirzepatide alone, it adds amylin satiety at the cost of a second weekly injection and overlapping GI side effects.
Sources & references
Frequently asked questions
Is there trial data for this exact combination?
Not specifically. Cagrilintide and tirzepatide are each well studied individually, and the amylin-plus-incretin concept is validated clinically as CagriSema (with semaglutide), but cagrilintide plus tirzepatide has no dedicated trial — hence community confidence.
Should the two be titrated together?
Titrate each on its own schedule using separate vials. Cagrilintide steps up in parallel toward 2.4 mg while tirzepatide follows its standard 2.5 mg-every-four-weeks escalation; separating them lets you back off one component if GI tolerability becomes an issue.
Is this stronger than CagriSema?
On paper the tirzepatide base is a more potent incretin mechanism than semaglutide, so the ceiling may be higher — but this is an inference. Only CagriSema has the controlled efficacy and safety data to support its figures.
For educational and research reference only. Not intended for human consumption, not medical advice. Compounds discussed are sold and used for laboratory research purposes only.
Related stacks
CagriSema (Cagrilintide + Semaglutide)
CagriSema combines a long-acting amylin analog (cagrilintide) with a GLP-1 agonist (semaglutide), each titrated toward 2.4 mg weekly. The two appetite mechanisms — amylin-mediated and GLP-1-mediated satiety — are additive, and the combination has advanced through Phase 3 (REDEFINE) as a fixed-dose product.
Cagrilintide + Retatrutide
This is the most aggressive weight-loss combination on paper: it stacks the long-acting amylin analog cagrilintide on top of retatrutide, the triple-G agonist that activates the GIP, GLP-1, and glucagon receptors at once. Retatrutide alone produced the largest weight reductions reported for any pharmacological agent in its Phase 2 trial — about 24% at 48 weeks, with the curve still falling — and the glucagon component adds an energy-expenditure mechanism on top of the appetite suppression shared with other incretins. Adding amylin-mediated satiety layers a fourth, mechanistically distinct hunger signal onto that base.